Literature DB >> 7693399

Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits.

F S Vargas1, N S Wang, H M Lee, S E Gruer, C S Sassoon, R W Light.   

Abstract

The two agents most commonly used for producing a pleurodesis are tetracycline and bleomycin. Tetracycline is no longer available due to more stringent requirements on the manufacturing process. The objective of this project was to determine whether bleomycin is an effective sclerosant in an experimental model in rabbits. The following medications were instilled intrapleurally in anesthetized male rabbits: tetracycline, 35 mg/kg, or bleomycin, 1.5 or 3.0 IU/kg diluted to a total volume of 1 ml with bacteriostatic saline solution. Twenty-eight days after the instillation, the animals were killed, and the pleural spaces were assessed grossly for evidence of pleurodesis and microscopically for evidence of fibrosis and inflammation. The intrapleural injection of bleomycin was ineffective in creating pleural fibrosis, either grossly or microscopically. The mean degree of gross pleurodesis in the six rabbits who received tetracycline was 2.7 +/- 1.5 (scale 0 to 4), while that in the rabbits who received the highest dose of bleomycin was 0.0 +/- 0.0. Based on this study, we recommend that bleomycin not be used as a pleural sclerosant in patients with nonneoplastic pleural disease, eg, those with pneumothorax, congestive heart failure or cirrhosis, and pleural effusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693399     DOI: 10.1378/chest.104.5.1582

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  BTS guidelines for the management of spontaneous pneumothorax.

Authors:  M Henry; T Arnold; J Harvey
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

3.  Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.

Authors:  R W Light; N S Wang; J A Despars; S E Gruer; C Sassoon; F S Vargas
Journal:  Lung       Date:  1996       Impact factor: 2.584

4.  Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications.

Authors:  Y C Lee; K B Lane; R E Parker; D S Ayo; J T Rogers; R W Diters; P J Thompson; R W Light
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

Review 5.  Treating Recurrent Pleural Disease: A Review of Indications and Technique for Chemical Pleurodesis for the Interventional Radiologist.

Authors:  Surbhi B Trivedi; Matthew Niemeyer
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

6.  Ultrastructural acute features of active remodeling after chemical pleurodesis induced by silver nitrate or talc.

Authors:  Eduardo H Genofre; Francisco S Vargas; Leila Antonangelo; Lisete R Teixeira; Marcelo A C Vaz; Evaldo Marchi; Vera Luiza Capelozzi
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

7.  Effectiveness of sodium hydroxide as a pleural sclerosing agent in rabbits: influence of concomitant intrapleural lidocaine.

Authors:  L R Teixeira; F S Vargas; A O Carmo; A Cukier; L M Silva; R W Light
Journal:  Lung       Date:  1996       Impact factor: 2.584

8.  Is Bleomycin a worthy alternative?

Authors:  Jyotsna Murthy
Journal:  Indian J Plast Surg       Date:  2011-01

9.  Hemoptysis following Talc Pleurodesis in a Pneumothorax Patient.

Authors:  Yusuke Kakiuchi; Fumihiro Yamaguchi; Makoto Hayashi; Yusuke Shikama
Journal:  Case Rep Pulmonol       Date:  2017-10-16

10.  Pleurodesis by erythromycin, tetracycline, Aerosil™ 200, and erythromycin plus Aerosil™ 200 in a rat model: a preliminary study.

Authors:  Shahryar Hashemzadeh; Khosrow Hashemzadeh; Kamran Mamaghani; Elnaz Ansari; Raheleh Aligholipour; Samad Ej Golzari; Kamyar Ghabili
Journal:  Daru       Date:  2012-11-26       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.